UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000021641
Receipt No. R000024899
Scientific Title Perioperative CapeOx therapy for clinical stage III gastric cancer; a phase II study (OGSG1601)
Date of disclosure of the study information 2016/04/01
Last modified on 2020/01/22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Perioperative CapeOx therapy for clinical stage III gastric cancer; a phase II study (OGSG1601)
Acronym Perioperative CapeOx therapy for clinical stage III gastric cancer; a phase II study (OGSG1601)
Scientific Title Perioperative CapeOx therapy for clinical stage III gastric cancer; a phase II study (OGSG1601)
Scientific Title:Acronym Perioperative CapeOx therapy for clinical stage III gastric cancer; a phase II study (OGSG1601)
Region
Japan

Condition
Condition Gastric Cancer
Classification by specialty
Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Eevaluate the efficacy of perioperative CapeOx therapy in patients with clinical stage III gastric cancer.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes pathological response rate
Key secondary outcomes 1.Percent completion (PC) of the protocol treatment
2.Relative Dose Intensity (RDI) of neoadjuvant chemotherapy
3.Percent completion of adjuvant chemotherapy
4.Overall survival
5.Relapse free survival
6.Response Rate (RR)
7.Incidence of adverse events on neoadjuvant chemotherapy
8.Incidence of a postoperative complication
9.Relative Dose Intensity(RDI) of adjuvant chemotherapy

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine Other
Interventions/Control_1 preoperative CapeOx therapy
Capecitabine : 1,000mg/m2 bid, day1-14, q3w
Oxaliplatin : 130mg/m2, day 1, q3w
3 cycle
Surgery
Postoperative CapeOx therapy
Capecitabine : 1,000mg/m2 bid, day1-14, q3w
Oxaliplatin : 130mg/m2, day 1, q3w
5 cycle
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Histologically proven gastric adenocarcinoma
2) Clinically diagnosed cSS/SE N1-3 MO gastric cancer
3) Aged 20 years old or over
4) ECOG performance status of 0 or 1
5) Possible oral intake
6) Adequate organ function
a. neutrophilic count : => 1500/mm3
b. hemoglobin : => 8g/dL
c. platelet : => 100,000/mm3
d. AST, ALT : =< 100 IU/L
e. total bilirubin : =< 2mg/dL
f. creatinine clearance : => 50mL/min
7) Wrriten informed consent from patient
Key exclusion criteria 1) With active double cancers
2) Past history of severe hypersensitivity to drugs
3) With active infection
4) Pregnant women, or women with the possibility of the pregnancy
5) Men who want let to pregnancy
6) History of myocardial infarction within 6 months
7) Continuous systemic steroid therapy
8) Under treatment with flucytosine, phenytoin
9) Severe diarrhea
10) Positive HBs antigen
11) Severe complications
12) Bulky lymph node metastasis, Borrmann type 4 or large type 3
13) Patients juged inappropriate for the study by the physicians
Target sample size 37

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Masahiro Gotou
Organization Osaka Medical College Hospital
Division name Chemotherapy Center
Zip code
Address 2-7 Daigaku-machi, Takatsuki City , Osaka, 569-8686
TEL 072-683-1211
Email in2030@poh.osaka-med.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Tetsuji Terazawa
Organization Osaka Medical College Hospital
Division name Chemotherapy Center
Zip code
Address 2-7 Daigaku-cho, Takatsuki, Osaka, 569-8686
TEL 072-683-1211
Homepage URL
Email terasawat@poh.osaka-med.ac.jp

Sponsor
Institute Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)
Institute
Department

Funding Source
Organization Yakult Honsha Co.,Ltd
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 大阪医科大学(大阪府)

Other administrative information
Date of disclosure of the study information
2016 Year 04 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 37
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2016 Year 02 Month 05 Day
Date of IRB
2016 Year 03 Month 07 Day
Anticipated trial start date
2016 Year 07 Month 07 Day
Last follow-up date
2020 Year 07 Month 04 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 03 Month 27 Day
Last modified on
2020 Year 01 Month 22 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024899

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.